
Substance Drug Abuse Market
Description
Substance Drug Abuse Market Report and Forecast 2024-2032
The substance drug abuse market was valued at USD 12 billion in 2023, driven by the increasing prevalence of substance abuse disorders and the rising demand for effective addiction treatments. Coupled with growing government initiatives and heightened awareness surrounding mental health, the market is expected to grow at a CAGR of 9%during the forecast period 2024-2032, reaching a market value of USD 25 billion by 2032.
Substance Drug Abuse Market Analysis
Substance drug abuse refers to the harmful or hazardous use of psychoactive substances, including alcohol, opioids, and other drugs. It leads to significant health, social, and psychological consequences, requiring comprehensive treatments that involve medication, counselling, and behavioural therapies. With the increasing prevalence of drug addiction globally, the substance drug abuse market is witnessing a surge in demand for treatment solutions, including medications such as methadone and behavioural therapy to support recovery and prevent relapse.
Market Drivers
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Substance Drug Abuse Market Segmentation
Market Breakup by Treatment
Drugs
Others
The substance drug abuse market is segmented by treatment into drugs (methadone, buprenorphine, naltrexone, and others), counselling and behavioural therapy, and others. Drug-based treatments, particularly methadone and buprenorphine, dominate the market due to their effectiveness in managing withdrawal symptoms and reducing dependency. Counselling and behavioural therapy play a crucial role in long-term recovery by addressing the psychological aspects of addiction.
Market Breakup by Route of Administration
Oral
Parenteral
Others
The market is segmented by route of administration into oral, parenteral, and others. Oral administration leads the market as it is the most common method for delivering medications like methadone and buprenorphine. Parenteral administration is used for more acute cases, while other emerging routes are gaining traction for their ability to improve drug efficacy and patient compliance.
Market Breakup by End User
Hospitals and Clinics
Rehabilitation Centers
Homecare Settings
Others
The substance drug abuse market is segmented by end-user into hospitals and clinics, rehabilitation centres, homecare settings, and others. Rehabilitation centres are the primary end users, providing comprehensive care for substance abuse disorders. Hospitals and clinics also play a significant role in offering medical detoxification and initial treatment, while homecare settings are growing in popularity for providing ongoing support in a more comfortable environment.
Market Breakup by Region
Substance Drug Abuse Market Competitive Landscape
The substance drug abuse market features key players such as Pfizer Inc., Mallinckrodt Pharmaceuticals, Rosemont Pharmaceuticals Limited, Spectrum Chemicals, Taj Pharmaceuticals Limited, VistaPharm LLC, Teva Pharmaceuticals Inc., Hikma Pharmaceutical PLC, Braeburn Inc., and Atlas Medical GmbH. These companies focus on the development and distribution of medications for addiction treatment, with a strong emphasis on innovation, patient compliance, and global expansion to meet rising demand.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the substance drug abuse market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the substance drug abuse market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the substance drug abuse industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The substance drug abuse market was valued at USD 12 billion in 2023, driven by the increasing prevalence of substance abuse disorders and the rising demand for effective addiction treatments. Coupled with growing government initiatives and heightened awareness surrounding mental health, the market is expected to grow at a CAGR of 9%during the forecast period 2024-2032, reaching a market value of USD 25 billion by 2032.
Substance Drug Abuse Market Analysis
Substance drug abuse refers to the harmful or hazardous use of psychoactive substances, including alcohol, opioids, and other drugs. It leads to significant health, social, and psychological consequences, requiring comprehensive treatments that involve medication, counselling, and behavioural therapies. With the increasing prevalence of drug addiction globally, the substance drug abuse market is witnessing a surge in demand for treatment solutions, including medications such as methadone and behavioural therapy to support recovery and prevent relapse.
Market Drivers
- Rising Prevalence of Substance Abuse Disorders: The increasing prevalence of substance abuse disorders globally is a key driver of market growth. The surge in opioid and alcohol addiction, particularly in high-stress environments and urban areas, is creating a growing demand for effective treatment options to combat the epidemic.
- Government Initiatives and Funding for Addiction Treatment: Governments across the world are implementing initiatives and increasing funding to address the growing issue of substance abuse. These programmes are aimed at expanding access to treatment, rehabilitation, and awareness, thus driving demand for treatment solutions in both public and private healthcare sectors.
- Development of Advanced Treatment Therapies: Innovations in drug formulations and behavioural therapies are contributing to the expansion of the substance drug abuse treatment market. New medications such as extended-release formulations of buprenorphine are improving patient compliance and outcomes, supporting the market’s growth trajectory.
- Increasing Focus on Mental Health and Addiction: The rising awareness of the link between mental health and substance abuse is driving greater demand for integrated treatment solutions. As healthcare providers adopt a more holistic approach to treating addiction, combining mental health support with drug treatment, the market is experiencing increased growth.
- Growing Availability of Treatment Options in Developing Regions: The increasing availability of addiction treatment options in emerging markets is driving growth in the substance drug abuse market. Regions such as Asia-Pacific and Latin America are witnessing expanded access to medication and behavioural therapies, supported by government and non-governmental organisations.
- Stigma Surrounding Addiction Treatment: The social stigma associated with substance abuse continues to pose a significant challenge to market growth. Many individuals with addiction issues avoid seeking treatment due to fear of judgement, limiting the number of patients who receive appropriate care.
- Risk of Relapse in Long-Term Treatment: Despite the availability of advanced treatment options, the risk of relapse remains a challenge in the substance abuse treatment market. Long-term treatment requires consistent monitoring and support, which can be difficult to maintain, leading to high relapse rates.
- Limited Access to Rehabilitation Centres in Rural Areas: Many rural areas, especially developing regions, lack adequate access to rehabilitation centres and addiction treatment facilities. This limited infrastructure poses a challenge for patients who require treatment but cannot access it due to geographical barriers.
- Strict Regulatory Frameworks for Drug Approval: The substance abuse treatment market is subject to strict regulatory scrutiny. The lengthy approval processes for new drugs, particularly opioid-based treatments, can delay product launches and limit the introduction of innovative therapies in the market.
- Development of New Non-Addictive Treatment Medications: The development of non-addictive medications for substance abuse treatment presents a significant growth opportunity. As concerns over opioid-based treatments grow, there is a rising demand for alternatives that effectively manage withdrawal symptoms without the risk of dependency.
- Expansion of Telemedicine and Digital Therapeutics: The adoption of telemedicine and digital health platforms for addiction treatment offers new opportunities for market growth. These technologies enable patients to access counselling and therapy remotely, increasing treatment reach, particularly in underserved regions.
- Rising Demand for Personalised Treatment Plans: Personalised treatment plans that are tailored to the specific needs of individuals based on their substance abuse history, genetic factors, and mental health status are gaining popularity. This approach offers more effective treatment outcomes and presents an opportunity for healthcare providers to expand service offerings.
- Growing Focus on Preventative Care: As awareness of the long-term consequences of substance abuse increases, there is a rising demand for preventative care programmes. These initiatives aim to educate populations on the risks of drug abuse and provide early intervention strategies, offering growth potential for the market.
- Increased Collaboration Between Public and Private Sectors: There are growing opportunities for collaboration between government agencies, healthcare providers, and private companies to address the substance abuse epidemic. Joint efforts to improve access to treatment, reduce stigma, and provide funding are expected to further drive market growth.
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Increasing Use of Medication-Assisted Treatment (MAT)
- Growth of Outpatient Treatment Services
- Focus on Integrated Care Models
- Adoption of Digital Health Tools in Treatment
- Rising Demand for Non-Opioid Treatment Alternatives
- Increasing Government and Non-Governmental Support for Rehabilitation Programmes
Substance Drug Abuse Market Segmentation
Market Breakup by Treatment
Drugs
- Methadone
- Buprenorphine
- Naltrexone
- Others
Others
The substance drug abuse market is segmented by treatment into drugs (methadone, buprenorphine, naltrexone, and others), counselling and behavioural therapy, and others. Drug-based treatments, particularly methadone and buprenorphine, dominate the market due to their effectiveness in managing withdrawal symptoms and reducing dependency. Counselling and behavioural therapy play a crucial role in long-term recovery by addressing the psychological aspects of addiction.
Market Breakup by Route of Administration
Oral
Parenteral
Others
The market is segmented by route of administration into oral, parenteral, and others. Oral administration leads the market as it is the most common method for delivering medications like methadone and buprenorphine. Parenteral administration is used for more acute cases, while other emerging routes are gaining traction for their ability to improve drug efficacy and patient compliance.
Market Breakup by End User
Hospitals and Clinics
Rehabilitation Centers
Homecare Settings
Others
The substance drug abuse market is segmented by end-user into hospitals and clinics, rehabilitation centres, homecare settings, and others. Rehabilitation centres are the primary end users, providing comprehensive care for substance abuse disorders. Hospitals and clinics also play a significant role in offering medical detoxification and initial treatment, while homecare settings are growing in popularity for providing ongoing support in a more comfortable environment.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Substance Drug Abuse Market Competitive Landscape
The substance drug abuse market features key players such as Pfizer Inc., Mallinckrodt Pharmaceuticals, Rosemont Pharmaceuticals Limited, Spectrum Chemicals, Taj Pharmaceuticals Limited, VistaPharm LLC, Teva Pharmaceuticals Inc., Hikma Pharmaceutical PLC, Braeburn Inc., and Atlas Medical GmbH. These companies focus on the development and distribution of medications for addiction treatment, with a strong emphasis on innovation, patient compliance, and global expansion to meet rising demand.
Key Questions Answered in the Report
- What are the main drivers of growth in the substance drug abuse market?
- How does the increasing prevalence of opioid addiction impact the market?
- What challenges does the market face in terms of stigma and access to treatment?
- How is the market segmented by treatment type and route of administration?
- What opportunities exist for non-opioid treatment alternatives?
- How are digital health tools transforming addiction treatment?
- What role do government initiatives play in expanding access to addiction treatment?
- How is the rise of outpatient services contributing to market growth?
- What are the key trends in medication-assisted treatment (MAT) for substance abuse?
- How does the competitive landscape influence product development in the market?
- How is the market growing in regions such as Japan and India?
- What are the future opportunities for collaboration between public and private sectors?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the substance drug abuse market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the substance drug abuse market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the substance drug abuse industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Substance Drug Abuse Market Overview – 8 Major Markets
- 3.1 Substance Drug Abuse Market Historical Value (2018-2024)
- 3.2 Substance Drug Abuse Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Substance Drug Abuse Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Substance Drug Abuse Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Substance Drug Abuse Market Landscape – 8 Major Markets
- 8.1 Substance Drug Abuse Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Substance Drug Abuse Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 8.2.2 Analysis by Route of Administration
- 9 Substance Drug Abuse Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Substance Drug Abuse Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Substance Drug Abuse Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Substance Drug Abuse Market (2018-2034) by Treatment
- 12.1.1 Market Overview
- 12.1.2 Drugs
- 12.1.2.1 Methadone
- 12.1.2.2 Buprenorphine
- 12.1.2.3 Naltrexone
- 12.1.2.4 Others
- 12.1.3 Counselling & Behavioral Therapy
- 12.1.4 Others
- 12.2 Substance Drug Abuse Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Others
- 12.3 Substance Drug Abuse Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals & Clinics
- 12.3.3 Rehabilitation Centers
- 12.3.4 Homecare Settings
- 12.3.5 Others
- 12.4 Substance Drug Abuse Market (2018-2034) by Country
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States Substance Drug Abuse Market (2018-2034)
- 13.1 United States Substance Drug Abuse Market Historical Value (2018-2024)
- 13.2 United States Substance Drug Abuse Market Forecast Value (2025-2034)
- 13.3 United States Substance Drug Abuse Market (2018-2034) by Treatment
- 13.3.1 Market Overview
- 13.3.2 Drugs
- 13.3.2.1 Methadone
- 13.3.2.2 Buprenorphine
- 13.3.2.3 Naltrexone
- 13.3.2.4 Others
- 13.3.3 Counselling & Behavioral Therapy
- 13.3.4 Others
- 13.4 United States Substance Drug Abuse Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Others
- 13.5 United States Substance Drug Abuse Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals & Clinics
- 13.5.3 Rehabilitation Centers
- 13.5.4 Homecare Settings
- 13.5.5 Others
- 14 United Kingdom Substance Drug Abuse Market (2018-2034)
- 14.1 United Kingdom Substance Drug Abuse Market Historical Value (2018-2024)
- 14.2 United Kingdom Substance Drug Abuse Market Forecast Value (2025-2034)
- 14.3 United Kingdom Substance Drug Abuse Market (2018-2034) by Treatment
- 14.3.1 Market Overview
- 14.3.2 Drugs
- 14.3.2.1 Methadone
- 14.3.2.2 Buprenorphine
- 14.3.2.3 Naltrexone
- 14.3.2.4 Others
- 14.3.3 Counselling & Behavioral Therapy
- 14.3.4 Others
- 14.4 United Kingdom Substance Drug Abuse Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Others
- 14.5 United Kingdom Substance Drug Abuse Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals & Clinics
- 14.5.3 Rehabilitation Centers
- 14.5.4 Homecare Settings
- 14.5.5 Others
- 15 France Substance Drug Abuse Market (2018-2034)
- 15.1 France Substance Drug Abuse Market Historical Value (2018-2024)
- 15.2 France Substance Drug Abuse Market Forecast Value (2025-2034)
- 15.3 France Substance Drug Abuse Market (2018-2034) by Treatment
- 15.3.1 Market Overview
- 15.3.2 Drugs
- 15.3.2.1 Methadone
- 15.3.2.2 Buprenorphine
- 15.3.2.3 Naltrexone
- 15.3.2.4 Others
- 15.3.3 Counselling & Behavioral Therapy
- 15.3.4 Others
- 15.4 France Substance Drug Abuse Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Others
- 15.5 France Substance Drug Abuse Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals & Clinics
- 15.5.3 Rehabilitation Centers
- 15.5.4 Homecare Settings
- 15.5.5 Others
- 16 Italy Substance Drug Abuse Market (2018-2034)
- 16.1 Italy Substance Drug Abuse Market Historical Value (2018-2024)
- 16.2 Italy Substance Drug Abuse Market Forecast Value (2025-2034)
- 16.3 Italy Substance Drug Abuse Market (2018-2034) by Treatment
- 16.3.1 Market Overview
- 16.3.2 Drugs
- 16.3.2.1 Methadone
- 16.3.2.2 Buprenorphine
- 16.3.2.3 Naltrexone
- 16.3.2.4 Others
- 16.3.3 Counselling & Behavioral Therapy
- 16.3.4 Others
- 16.4 Italy Substance Drug Abuse Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Others
- 16.5 Italy Substance Drug Abuse Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals & Clinics
- 16.5.3 Rehabilitation Centers
- 16.5.4 Homecare Settings
- 16.5.5 Others
- 17 Spain Substance Drug Abuse Market (2018-2034)
- 17.1 Spain Substance Drug Abuse Market Historical Value (2018-2024)
- 17.2 Spain Substance Drug Abuse Market Forecast Value (2025-2034)
- 17.3 Spain Substance Drug Abuse Market (2018-2034) by Treatment
- 17.3.1 Market Overview
- 17.3.2 Drugs
- 17.3.2.1 Methadone
- 17.3.2.2 Buprenorphine
- 17.3.2.3 Naltrexone
- 17.3.2.4 Others
- 17.3.3 Counselling & Behavioral Therapy
- 17.3.4 Others
- 17.4 Spain Substance Drug Abuse Market (2018-2034) by Route of Administration
- 17.4.1 Market Overview
- 17.4.2 Oral
- 17.4.3 Parenteral
- 17.4.4 Others
- 17.5 Spain Substance Drug Abuse Market (2018-2034) by End User
- 17.5.1 Market Overview
- 17.5.2 Hospitals & Clinics
- 17.5.3 Rehabilitation Centers
- 17.5.4 Homecare Settings
- 17.5.5 Others
- 18 Japan Substance Drug Abuse Market
- 18.1 Japan Substance Drug Abuse Market Historical Value (2018-2024)
- 18.2 Japan Substance Drug Abuse Market Forecast Value (2025-2034)
- 18.3 Japan Substance Drug Abuse Market (2018-2034) by Treatment
- 18.3.1 Market Overview
- 18.3.2 Drugs
- 18.3.2.1 Methadone
- 18.3.2.2 Buprenorphine
- 18.3.2.3 Naltrexone
- 18.3.2.4 Others
- 18.3.3 Counselling & Behavioral Therapy
- 18.3.4 Others
- 18.4 Japan Substance Drug Abuse Market (2018-2034) by Route of Administration
- 18.4.1 Market Overview
- 18.4.2 Oral
- 18.4.3 Parenteral
- 18.4.4 Others
- 18.5 Japan Substance Drug Abuse Market (2018-2034) by End User
- 18.5.1 Market Overview
- 18.5.2 Hospitals & Clinics
- 18.5.3 Rehabilitation Centers
- 18.5.4 Homecare Settings
- 18.5.5 Others
- 19 India Substance Drug Abuse Market
- 19.1 India Substance Drug Abuse Market (2018-2034) Historical Value (2018-2024)
- 19.2 India Substance Drug Abuse Market (2018-2034) Forecast Value (2025-2034)
- 19.3 India Substance Drug Abuse Market (2018-2034) by Treatment
- 19.3.1 Market Overview
- 19.3.2 Drugs
- 19.3.2.1 Methadone
- 19.3.2.2 Buprenorphine
- 19.3.2.3 Naltrexone
- 19.3.2.4 Others
- 19.3.3 Counselling & Behavioral Therapy
- 19.3.4 Others
- 19.4 India Substance Drug Abuse Market (2018-2034) by Route of Administration
- 19.4.1 Market Overview
- 19.4.2 Oral
- 19.4.3 Parenteral
- 19.4.4 Others
- 19.5 India Substance Drug Abuse Market (2018-2034) by End User
- 19.5.1 Market Overview
- 19.5.2 Hospitals & Clinics
- 19.5.3 Rehabilitation Centers
- 19.5.4 Homecare Settings
- 19.5.5 Others
- 20 Regulatory Framework
- 20.1 Regulatory Overview
- 20.2 US FDA
- 20.3 EU EMA
- 20.4 Japan PMDA
- 20.5 India CDSCO
- 20.6 Others
- 21 Patent Analysis
- 21.1 Analysis by Type of Patent
- 21.2 Analysis by Publication Year
- 21.3 Analysis by Issuing Authority
- 21.4 Analysis by Patent Age
- 21.5 Analysis by CPC Analysis
- 21.6 Analysis by Patent Valuation
- 21.7 Analysis by Key Players
- 22 Clinical Trials and Pipeline Analysis
- 22.1 Analysis by Trial Registration Year
- 22.2 Analysis by Trial Status
- 22.3 Analysis by Trial Phase
- 22.4 Analysis by Therapeutic Area
- 22.5 Analysis by Geography
- 22.6 Type Pipeline Assessment
- 23 Grants Analysis
- 23.1 Analysis by Year
- 23.2 Analysis by Amount Awarded
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Grant Application
- 23.5 Analysis by Funding Institute
- 23.6 Analysis by NIH Departments
- 23.7 Analysis by Recipient Organization
- 24 Funding and Investment Analysis
- 24.1 Analysis by Funding Instances
- 24.2 Analysis by Type of Funding
- 24.3 Analysis by Funding Amount
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Leading Investors
- 24.6 Analysis by Geography
- 25 Strategic Initiatives
- 25.1 Analysis by Partnership Instances
- 25.2 Analysis by Type of Partnership
- 25.3 Analysis by Leading Players
- 25.4 Analysis by Geography
- 26 Supplier Landscape
- 26.1 Market Share by Top 5 Companies
- 26.2 Pfizer Inc.
- 26.2.1 Financial Analysis
- 26.2.2 Product Portfolio
- 26.2.3 Demographic Reach and Achievements
- 26.2.4 Companies News and Developments
- 26.2.5 Certifications
- 26.3 Mallinckrodt Pharmaceuticals
- 26.3.1 Financial Analysis
- 26.3.2 Product Portfolio
- 26.3.3 Demographic Reach and Achievements
- 26.3.4 Companies News and Developments
- 26.3.5 Certifications
- 26.4 Rosemont Pharmaceuticals Limited
- 26.4.1 Financial Analysis
- 26.4.2 Product Portfolio
- 26.4.3 Demographic Reach and Achievements
- 26.4.4 Companies News and Developments
- 26.4.5 Certifications
- 26.5 Spectrum Chemicals
- 26.5.1 Financial Analysis
- 26.5.2 Product Portfolio
- 26.5.3 Demographic Reach and Achievements
- 26.5.4 Companies News and Developments
- 26.5.5 Certifications
- 26.6 Taj Pharmaceuticals Limited
- 26.6.1 Financial Analysis
- 26.6.2 Product Portfolio
- 26.6.3 Demographic Reach and Achievements
- 26.6.4 Companies News and Developments
- 26.6.5 Certifications
- 26.7 VistaPharm LLC
- 26.7.1 Financial Analysis
- 26.7.2 Product Portfolio
- 26.7.3 Demographic Reach and Achievements
- 26.7.4 Companies News and Developments
- 26.7.5 Certifications
- 26.8 Teva Pharmaceuticals Inc.
- 26.8.1 Financial Analysis
- 26.8.2 Product Portfolio
- 26.8.3 Demographic Reach and Achievements
- 26.8.4 Companies News and Developments
- 26.8.5 Certifications
- 26.9 Hikma Pharmaceutical PLC
- 26.9.1 Financial Analysis
- 26.9.2 Product Portfolio
- 26.9.3 Demographic Reach and Achievements
- 26.9.4 Companies News and Developments
- 26.9.5 Certifications
- 26.10 Atlas Medical GmbH
- 26.10.1 Financial Analysis
- 26.10.2 Product Portfolio
- 26.10.3 Demographic Reach and Achievements
- 26.10.4 Companies News and Developments
- 26.10.5 Certifications
- 26.11 Braeburn Inc.
- 26.11.1 Financial Analysis
- 26.11.2 Product Portfolio
- 26.11.3 Demographic Reach and Achievements
- 26.11.4 Companies News and Developments
- 26.11.5 Certifications
- 27 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.